Neomycin/fluocinolone (Neo-Synalar) topical cream coverage criteria
Customize your policy alerts
Sign up for Health Net Policy CP PMN.167 alerts
Get alerted when Policy CP PMN.167 changes without checking for updates manually.
Monitor payer policy activity
Policy governs medical necessity and prior authorization criteria for Neo-Synalar topical cream for members across Commercial, HIM, and Medicaid lines of business.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial Approval Criteria
Covered when ALL of the following are met:
Initial Approval
- Diagnosis of a corticosteroid-responsive dermatosis (examples include eczema, psoriasis, poison ivy/oak/sumac, insect bites, atopic dermatitis, seborrheic dermatitis).
- Failure of a formulary topical antibacterial product at up to maximally indicated doses (see Appendix B) unless clinically significant adverse effects are experienced or all such agents are contraindicated.
Dose limits
- Two tubes per treatment course.
- Does not exceed 120 g per treatment course.
Re-authorization is not permitted; members must meet initial approval criteria for any subsequent request.
Other Diagnoses/Indications
For uses not meeting initial criteria:
Alternate pathways
- If the drug is on the formulary/PDL for the relevant line of business, follow the no coverage criteria policy for that line (CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, CP PMN.255 for Medicaid).
- If the drug is NOT on the formulary/PDL for the relevant line of business, follow the non-formulary policy for that line (CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, CP PMN.16 for Medicaid).
- If the requested use (e.g., diagnosis, age, dosing regimen) is not listed in the policy’s section for non-authorized indications AND the initial approval criteria do not apply, refer to the off-label use policy for the relevant line of business (CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, CP PMN.53 for Medicaid).
Requests for Neo-Synalar use for indications that are not FDA‑approved and are not specifically addressed in this policy will not be authorized unless the provider supplies sufficient documentation of efficacy and safety per the applicable off‑label use policy for the member's line of business (see CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP PMN.53 for Medicaid).
Contraindications include known hypersensitivity to any component of the preparation. Do not use Neo‑Synalar in the external auditory canal when the tympanic membrane is perforated. No boxed warnings are reported for this product.
Neo‑Synalar combines an antibiotic and corticosteroid for corticosteroid‑responsive dermatoses with secondary infection. The manufacturer notes that the combination has not been demonstrated to provide greater benefit than the steroid component alone after 7 days of treatment, so use beyond 7 days is generally not supported by evidence of added effectiveness.
Coding and Dosing Limits
Provider Actions and Requirements
Prior Authorization Required
Prior Authorization Required — documentation must show initial approval criteria are met. Provider must submit supporting clinical documentation (e.g., office chart notes, lab results, other clinical information) that demonstrates the member meets all approval criteria.
- Prior authorization required before coverage.
- Supporting documentation must include office notes, relevant labs, and treatment history.
Step Therapy Requirement
Step therapy requirement: member must have failed a formulary topical antibacterial at up to maximally indicated doses prior to approval, unless there is a documented contraindication or clinically significant adverse effect. See Appendix B for examples and dosing limits of formulary topical antibacterial alternatives.
- Failure of a formulary topical antibacterial at maximally indicated doses is required prior to approval.
- Exceptions allowed for documented contraindication or clinically significant adverse effects.
Required Documentation
Required documentation — provider must submit supporting clinical documentation to demonstrate criteria are met.
- Office chart notes describing diagnosis and prior therapies tried.
- Laboratory results, if relevant to the diagnosis or safety monitoring.
- Documentation of adverse reactions or contraindications if step therapy was bypassed.
Denial Triggers
Denial triggers — authorization may be denied if documentation is incomplete or if the requested use is a non‑FDA indication without sufficient off‑label evidence per applicable off‑label policies.
- Lack of supporting documentation of diagnosis or prior therapy attempts.
- Requests for non‑FDA approved indications without sufficient evidence per off‑label use policies (CP.CPA.09, HIM.PA.154, CPPMN.53, or evidence of coverage).
Background
Neo‑Synalar (neomycin/fluocinolone) is a topical cream that combines an antibacterial agent (neomycin) with a corticosteroid (fluocinolone) and is indicated for the treatment of corticosteroid‑responsive dermatoses with secondary infection. It is intended to address both inflammation and localized bacterial infection when those conditions coexist.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.